Augmenix

Client Overview

Augmenix is a medical device company that focuses on developing and commercializing innovative products that improve the quality of life for cancer patients. Their flagship product, SpaceOAR® Hydrogel, is designed to protect surrounding tissue during radiation therapy for prostate cancer.

Problem

Augmenix needed a way to explain the benefits and features of their SpaceOAR® Hydrogel product to potential investors, customers, and patients. The product's unique mechanism of action, which involves injecting a gel to create space between the prostate and the rectum, was difficult to convey through traditional marketing materials.

Solution

Augmenix partnered with Ghost Productions, a medical animation and graphics company, to create a series of animations and medical graphics that effectively communicated the benefits of SpaceOAR® Hydrogel to their target audience. Ghost Productions worked closely with Augmenix's team to understand the product's mechanism of action and create a visual representation of the process.

Results

The animations and medical graphics produced by Ghost Productions proved to be instrumental in helping Augmenix explain the benefits of SpaceOAR® Hydrogel to their target audience. The visual aids helped potential investors, customers, and patients understand the product's mechanism of action and the benefits of using it during radiation therapy for prostate cancer. The effectiveness of the animations and medical graphics created by Ghost Productions was demonstrated by Augmenix's successful acquisition by Boston Scientific. In September 2018, Boston Scientific announced that it had acquired Augmenix for $600 million, citing the potential of SpaceOAR® Hydrogel as a key factor in the acquisition.

Conclusion

The partnership between Augmenix and Ghost Productions demonstrates the value of using medical animations and graphics to effectively communicate complex medical concepts to target audiences. The success of the partnership was demonstrated by Augmenix's successful acquisition by Boston Scientific and the potential of SpaceOAR® Hydrogel to improve the quality of life for cancer patients undergoing radiation therapy for prostate cancer.

‍